Structured evidence table for Maca Sexual Function Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Maca Sexual Function Randomized Trial | It drives many physiological, emotional, and mental shifts that occur during this transition, including vasomotor symptoms, bone loss, alterations in body composition, changes in mood and cognition, and increased cardiometabolic risk []. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Sexual Function Randomized Trial | 29 30 31 32 33 Historically, this rise with the transition from the reproductive to menopausal stage of life has been interpreted primarily as a compensatory response to declining ovarian function and reduced negative feedback from the ovaries []. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Sexual Function Randomized Trial | 34 35 36 37 34 38 39 40 Another point of consideration is the evidence accumulating for FSH’s actions beyond the ovary. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Sexual Function Randomized Trial | 1 2 3 4 Over the past two decades, perimenopause and menopause have emerged as prominent topics in medical and public discourse. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
Source documents